3//SEC Filing
BAYER AKTIENGESELLSCHAFT 3
Accession 0001578563-21-000036
CIK 0001782223other
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 9:18 PM ET
Size
8.2 KB
Accession
0001578563-21-000036
Insider Transaction Report
Form 3
Bayer World Investments B.V.
10% Owner
Holdings
Series B Convertible Preferred Stock
→ Common Stock (955,507 underlying)Series A Convertible Preferred Stock
→ Common Stock (1,786,831 underlying)
BAYER AKTIENGESELLSCHAFT
10% Owner
Holdings
Series A Convertible Preferred Stock
→ Common Stock (1,786,831 underlying)Series B Convertible Preferred Stock
→ Common Stock (955,507 underlying)
Footnotes (3)
- [F1]Shares of Series A and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") have no expiration date and, as of the date of this filing, are convertible, at the option of the Reporting Persons, into shares of the Issuer's common stock at a 6.359-for-1 conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares).
- [F2]Reflects that each 6.359 shares of Preferred Stock will convert automatically into one share of the Issuer's common stock at the closing of the Issuer's initial public offering, for no additional consideration (subject to the payment of cash in lieu of any fractional shares).
- [F3]The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Documents
Issuer
Pyxis Oncology, Inc.
CIK 0001782223
Entity typeother
Related Parties
1- filerCIK 0001144145
Filing Metadata
- Form type
- 3
- Filed
- Oct 6, 8:00 PM ET
- Accepted
- Oct 7, 9:18 PM ET
- Size
- 8.2 KB